ArticleBlood2013
Clonal genetic and hematopoietic heterogeneity among human-induced pluripotent stem cell lines.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 78 citations in OpenAlex.
- Induced Pluripotent Stem Cells derived CD71International journal of stem cells · 2026Article
- Modeling primitive and definitive erythropoiesis with induced pluripotent stem cells.Blood advances · 2024Article
- Oligodendrogenesis and myelination tracing in a CRISPR/Cas9-engineered brain microphysiological system.Frontiers in cellular neuroscience · 2022Article
- Plating human iPSC lines on micropatterned substrates reveals role for ITGB1 nsSNV in endoderm formation.Stem cell reports · 2021Article
- Cerebral organoids as tools to identify the developmental roots of autism.Molecular autism · 2020Review
- Tropomyosin 1 genetically constrains in vitro hematopoiesis.BMC biology · 2020Article
- Modeling Alzheimer's disease with iPSC-derived brain cells.Molecular psychiatry · 2020Review
- Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.Haematologica · 2020Article
- Targeted Repair of p47-CGD in iPSCs by CRISPR/Cas9: Functional Correction without Cleavage in the Highly Homologous Pseudogenes.Stem cell reports · 2019Article
- Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.Blood advances · 2019Article
- Differentiation of diabetic foot ulcer-derived induced pluripotent stem cells reveals distinct cellular and tissue phenotypes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Comparative AAV-eGFP Transgene Expression Using Vector Serotypes 1-9, 7m8, and 8b in Human Pluripotent Stem Cells, RPEs, and Human and Rat Cortical Neurons.Stem cells international · 2019Article
- GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells.Blood advances · 2018Article
- Corneal cell therapy: with iPSCs, it is no more a far-sight.Stem cell research & therapy · 2018Review
- NIPBLScientific reports · 2018Article
- Modeling of Autism Using Organoid Technology.Molecular neurobiology · 2017Review
- ESRP1 Mutations Cause Hearing Loss due to Defects in Alternative Splicing that Disrupt Cochlear Development.Developmental cell · 2017Article
- Article
- Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin.Hepatology (Baltimore, Md.) · 2017Article
- Direct Reprogramming Rather than iPSC-Based Reprogramming Maintains Aging Hallmarks in Human Motor Neurons.Frontiers in molecular neuroscience · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Funding
Abstract
Induced pluripotent stem cells (iPSCs) hold great promise for modeling human hematopoietic diseases. However, intrinsic variability in the capacities of different iPSC lines for hematopoietic development complicates comparative studies and is currently unexplained. We created and analyzed 3 separate iPSC clones from fibroblasts of 3 different normal individuals using a standardized approach that included excision of integrated reprogramming genes by Cre-Lox mediated recombination. Gene expression profiling and hematopoietic differentiation assays showed that independent lines from the same individual were generally more similar to one another than those from different individuals. However, one iPSC line (WT2.1) exhibited a distinctly different gene expression, proliferation rate, and hematopoietic developmental potential relative to all other iPSC lines. This "outlier" clone also acquired extensive copy number variations (CNVs) during reprogramming, which may be responsible for its divergent properties. Our data indicate how inherent and acquired genetic differences can influence iPSC properties, including hematopoietic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.